Physicians underdiagnose and undertreat obesity in ishemic heart disease patients: Data from the HOLEM study group

被引:0
作者
Leibovitz, Eyal
Gerber, Yariv
Maislos, Maximo
Wolfovitz, Efrat
Chajek-Shaul, Tova
Leitersdorf, Eran
Goldbourt, Uri
Harats, Dror
机构
[1] Sheba Med Ctr, Inst Lipid & Atherosclerosis Res, Tel Hashomer, Israel
[2] Soroka Univ Med Ctr, Atherosclerosis Unit, Dept Med, Beer Sheva, Israel
[3] Rambam Med Ctr, Dept Internal Med D, Haifa, Israel
[4] Hadassah Univ Hosp, Dept Med, IL-91240 Jerusalem, Israel
[5] Hebrew Univ Jerusalem, Sch Med, IL-91010 Jerusalem, Israel
[6] Hadassah Univ Hosp, Dept Med B, Ctr Res Prevent & Treatment Atherosclerosis, Jerusalem, Israel
[7] Wolfson Med Ctr, Dept Med A, Holon, Israel
[8] Tel Aviv Univ, Sackler Fac Med, Div Epidemiol & Prevent Med, Ramat Aviv, Israel
[9] Sheba Med Ctr, Neufelo Cardiac Res Inst, Tel Hashomer, Israel
来源
ISRAEL MEDICAL ASSOCIATION JOURNAL | 2006年 / 8卷 / 08期
关键词
ischemic heart disease; risk factors; obesity; physicians; quality assurance;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Obesity is an independent risk factor for ischemic heart disease and affects the status of other risk factors for cardiovascular disease. Objective: To study the attitude of physicians to obesity by examining discharge letters of overweight patients with ischemic heart disease. Methods: We used the HOLEM database for this analysis. The HOLEM project was designed to study the NCEP (National Cholesterol Education Program) guideline implementation among patients with IHD at hospital discharge. We documented the recording of risk factors and treatment recommendations for IHD by reviewing the discharge letters of 2994 IHD patients admitted to four central hospitals in Israel between 1998 and 2000. A follow-up visit was held 6-8 weeks after discharge, at which time the diagnosis of IHD was verified, risk factor status was checked, height and weight were measured and drug treatment was reviewed. Results: Mean body mass index was 28.3 kg/m(2) and 32% were obese (BMI >= 30 30 kg/m(2)). Only 39.6% of the obese patients and 65.8% of the morbidly obese patients (BMI >= 40 kg/m(2)) had "obesity" noted in their discharge letters, and weight loss recommendation was written in only 15% of the obese patients' discharge letters. Acute episodes like acute myocardial infarction and unstable angina did not influence the notation of obesity, and only BMI and the number of additional risk factors were positively correlated with the notation of this risk factor. Conclusions: Despite the importance of obesity, weight status was not noted and weight loss was not recommended in most of the discharge letters of obese IHD patients.
引用
收藏
页码:553 / 557
页数:5
相关论文
共 24 条
[1]   Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension [J].
Bakris, G ;
Calhoun, D ;
Egan, B ;
Hellmann, C ;
Dolker, M ;
Kingma, I .
JOURNAL OF HYPERTENSION, 2002, 20 (11) :2257-2267
[2]   Factor V Leiden and morbid obesity in fatal postoperative pulmonary embolism [J].
Blaszyk, H ;
Björnsson, J .
ARCHIVES OF SURGERY, 2000, 135 (12) :1410-1413
[3]   ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-Segment elevation myocardial infarction - Summary article - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina) [J].
Braunwald, E ;
Antman, EM ;
Beasley, JW ;
Califf, RM ;
Cheitlin, MD ;
Hochman, JS ;
Jones, RH ;
Kereiakes, D ;
Kupersmith, J ;
Levin, TN ;
Pepine, CJ ;
Schaeffer, JW ;
Smith, EE ;
Steward, DE ;
Theroux, P ;
Gibbons, RJ ;
Alpert, JS ;
Faxon, DP ;
Fuster, V ;
Gregoratos, G ;
Hiratzka, LF ;
Jacobs, AK ;
Smith, SC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (07) :1366-1374
[4]  
BROWN LM, 1995, J NATL CANCER I, V87, P104, DOI 10.1093/jnci/87.2.104
[5]  
CAMBELL BS, 1994, AM J PUBLIC HEALTH, V84, P783
[6]   Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat - A randomized controlled trial [J].
Davidson, MH ;
Hauptman, J ;
DiGirolamo, M ;
Foreyt, JP ;
Halsted, CH ;
Heber, D ;
Heimburger, DC ;
Lucas, CP ;
Robbins, DC ;
Chung, J ;
Heymsfield, SB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (03) :235-242
[7]   Sleep disturbance and obesity - Changes following surgically induced weigh loss [J].
Dixon, JB ;
Shachter, LM ;
O'Brien, PE .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (01) :102-106
[8]   Type 2 diabetes mellitus in UK children - an emerging problem [J].
Ehtisham, S ;
Barrett, TG ;
Shaw, NJ .
DIABETIC MEDICINE, 2000, 17 (12) :867-871
[9]   Obesity and hypertension [J].
El-Atat, F ;
Aneja, A ;
Mcfarlane, S ;
Sowers, J .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2003, 32 (04) :823-+
[10]   Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study [J].
Finer, N ;
Bloom, SR ;
Frost, GS ;
Banks, LM ;
Griffiths, J .
DIABETES OBESITY & METABOLISM, 2000, 2 (02) :105-112